One of the key take-aways from a wide-ranging hour-long panel discussion on emerging markets at Elsevier Business Intelligence's 20th Pharmaceutical Strategic Alliances meeting was the notion that drugmakers cannot implement a one-size-fits-all strategy when building a presence in important new markets. Participating in the forum were Mervyn Turner, PhD, chief strategy officer of Merck , Jean-Michel Halfon, president and general manager of Pfizer's emerging markets business unit, and Robin Arnold, a consultant with IMS Health.
Ellen Foster Licking
In the early 1980s, former Speaker of the House Tip O'Neill famously coined the phrase "all politics is local," articulating...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.
Big pharma plans to invest billions of dollars in US manufacturing to avoid tariffs proposed by the Trump Administration. However, the implementation of these plans may be delayed due to regulatory complexities and rising costs from tariffs, potentially impacting drug prices for consumers.
S2 Xpeed is driving the rapid growth of medtech and hardware start-ups in Europe. Operating under a "sweat equity" model, the program helps early-stage companies move from prototype to manufacturing readiness in exchange for equity.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.
